Premium
Novel antitumor dinuclear platinum (II) complexes with a new chiral tetradentate ligand as the carrier group
Author(s) -
Gao Chuanzhu,
Zhang Yan,
Wang Tianshuai,
Chen Ji,
Qian Yunxu,
Yang Bo,
Gou Shaohua,
Dong Peng,
Zhang Yingjie
Publication year - 2015
Publication title -
applied organometallic chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.53
H-Index - 71
eISSN - 1099-0739
pISSN - 0268-2605
DOI - 10.1002/aoc.3323
Subject(s) - chemistry , oxaliplatin , carboplatin , cytotoxicity , stereochemistry , ligand (biochemistry) , platinum , methylene , in vitro , a549 cell , biological activity , combinatorial chemistry , medicinal chemistry , cisplatin , cancer , receptor , biochemistry , chemotherapy , medicine , colorectal cancer , surgery , catalysis
Seven dinuclear platinum(II) complexes with a novel chiral tetradentate ligand, (1 R ,1′ R ,2 R ,2′ R )‐ N 1 , N 1′ ‐(1,4‐phenylenebis(methylene))dicyclohexane‐1,2‐diamine, were designed, synthesized and spectrally characterized. All the complexes were evaluated for their in vitro cytotoxicity against human HepG‐2, A549, HCT‐116 and MCF‐7 cancer cell lines. The results indicated that all compounds showed positive biological activity against HepG‐2, A549 and HCT‐116 cancer cell lines. In particular, compounds D7 and D2 showed better activity than carboplatin against HepG‐2 and A549 and compound D7 also showed an activity close to that of oxaliplatin. Copyright © 2015 John Wiley & Sons, Ltd.